{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-010537","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.211548+00:00","generated_at":"2026-05-21T04:44:53.089048+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cocrystal Pharma Q1 net loss $2.3M, cash $6.9M; CDI-988 shows broad norovirus activity, human challenge planned","bullets":["Net loss for Q1 2025 was $2.3M ($0.23/share) vs $4.0M ($0.39/share) in Q1 2024.","R&D expenses decreased to $1.4M from $3.0M; G&A down to $1.0M from $1.2M.","Unrestricted cash $6.9M at March 31, 2025 vs $9.9M at Dec 31, 2024; working capital $6.9M.","CDI-988 showed superior broad-spectrum antiviral activity against norovirus GII.17 strains; expects to report topline Phase 1 high-dose results in Q2 2025.","Plan to initiate a U.S. human challenge study for CDI-988 as norovirus treatment and prophylaxis in coming months."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-010537","json":"https://secwatch.observer/filing/0001641172-25-010537.json","markdown":"https://secwatch.observer/filing/0001641172-25-010537.md","text":"https://secwatch.observer/filing/0001641172-25-010537.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000164117225010537/0001641172-25-010537-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000164117225010537/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:44:53.089048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}